Summary
Patients and methods
Patients with physician-diagnosed asthma attending a hospital asthma clinic were considered for the study. Eligible patients had to be using a Ventolin metered-dose inhaler as their usual relief medication at least twice daily with a technique assessed as adequate by the Asthma Nurse. Patients who had received a course of oral steroids within the previous month were ineligible. The patients used a Wright's mini peak flow meter to record their peak flow rate before and 20 minutes after using their relief therapy on rising and once prior to therapy in the evening. After their morning dose they were asked to use their relief inhaler only when required and the number of puffs used daily was recorded.
After a two week run-in period on their usual Ventolin inhaler, patients used Ventolin, 'blinded' Ventolin and salbutamol (Norton Health Care) inhalers for two weeks each in random order; the latter two inhalers were delivered via similar blanked cartidges and white actuators. At the end of each two-week treatment period, patients underwent spirometry before and 20 minutes after using their relief inhaler, and were asked to compare their current relief inhaler with their usual Ventolin inhaler using a 5-point scale (much worse, worse, as good as, better, much better). At the end of the study period they were asked if there were any of the three inhalers they would not like their doctor to prescribe and whether they preferred any one inhaler to the other two.
Measure of reversibility were calculated as follows: Step 2:4 (10%)
Step 3:16 (40%)
Step 4:17 (42.5%)
Step 5:3 (7.5%) This study provides clinical data to show that generic salbutamol is equivalent in efficacy to the branded product in the day-to-day control of a group of asthmatic patients who all require daily prophylactic therapy and relief medication for their asthma. Based on current usage and prices, if all patients currently using a Ventolin metered-dose inhaler were converted to the generic product, the savings in Scotland alone would be in excess of £1.5 million per annum. These savings would go some way to off-set the increasing costs of medication, generally encouraged as reflecting good quality asthma care.
For the future, our data on patients' own assessment of their relief inhaler suggests that a great deal of care will be required when converting patients from their usual inhaler to a CFC-free product. Fortunately data is now available showing that at least one CFC-free formulation is pharmacologically equivalent to the current branded product4 and this should help convince doctors at least, that the new product can be prescribed with confidence. Convincing the patient may prove more difficult. 
